Business
Obtaining approval of a BLA for a new biological product is a lengthy process, from the development of a new product through preclinical and clinical testing.
Vericel Corp: Revenue grew 16.5% to $276M from $237M. Net income grew 59.4% to $16.52M from $10.36M. Free cash flow turned positive at $24.75M from a $5.811M outflow. Operating margin expanded 210 bps to 4.00%. Vericel Corp's principal statistical and annual-change screens add no overriding warning to the reported profit and cash-flow record.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 16.5% to $276M from $237MOK
- Profitability — Net income grew 59.4% to $16.52M from $10.36MOK
- Cash flow — Free cash flow turned positive at $24.75M from a $5.811M outflowOK
- Margins — Operating margin expanded 210 bps to 4.00%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 20 salesWatch
Where the revenue comes from
Fiscal 2025, as Vericel Corp reports it. History and quarterly detail are in the app.
- Total MACI implants, kits, and instruments$239.5M
- MACI implants, kits, and instruments$180.2M
- Epicel$32.1M
- Biopsy kits and instruments - direct bill$2.6M
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-05-07
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Vericel Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.